SCHEMBL4099475

SCHEMBL4099475

Nc1ncc(-c2cccc(-c3c[nH]c4ccccc34)c2)c(NCCCN2CCNC2)n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDO2 P48775 2/20 0.42
CDK5 Q00535 4/20 0.40
CDK5R1 Q15078 4/20 0.40
CLK1 P49759 4/20 0.40
IRAK4 Q9NWZ3 3/20 0.39
HTR1A P08908 2/20 0.37
DRD2 P14416 2/20 0.37
HTR2A P28223 2/20 0.37
HTR7 P34969 2/20 0.37
HTR6 P50406 2/20 0.37
FGFR1 P11362 1/20 0.36
KDR P35968 1/20 0.36
PIM1 P11309 1/20 0.36
PIM3 Q86V86 1/20 0.36
PIM2 Q9P1W9 1/20 0.36
PRKACA P17612 1/20 0.35
PRKACG P22612 1/20 0.35
PRKACB P22694 1/20 0.35
CAMK2D Q13557 1/20 0.35
GSK3B P49841 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4106463 0.95 TDO2 (0.47) TDO2CDK5CDK5R1CLK1IRAK4
SCHEMBL4112182 0.90 ACP1 (0.45) CDK5CDK5R1CLK1IRAK4HTR1A
SCHEMBL4120199 0.89 ACP1 (0.46) CDK5CDK5R1CLK1IRAK4HTR1A
SCHEMBL4117379 0.88 FGFR1 (0.49) CDK5CDK5R1CLK1IRAK4HTR1A
SCHEMBL4100394 0.88 CDK5 (0.42) TDO2CDK5CDK5R1CLK1IRAK4
SCHEMBL4120931 0.87 IRAK4 (0.53) TDO2IRAK4
SCHEMBL4107204 0.87 CLK1 (0.40) TDO2CDK5CDK5R1CLK1IRAK4
SCHEMBL4107261 0.87 CDK5 (0.40) TDO2CDK5CDK5R1CLK1IRAK4
SCHEMBL3979571 0.85 DHFR (0.43) IRAK4HTR1AHTR7FGFR1KDR
SCHEMBL4108348 0.85 VCP (0.44) IRAK4FGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines DJUNG JANE F 2007-12-20 US claimed
US-8354407-B2 2-anilino-4-(heterocyclic)amino-pyrimidines BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-01-15 US disclosed
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-09-10 US disclosed
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines DJUNG JANE F 2007-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293494-A1 2-Anilino-4-(Heterocyclic) Amino-Pyrimidines PRKCA, PRKCG, PRKCH TDO2 2576/4885CDK5 69/4885CDK5R1 150/4885
US-20090227586-A1 2-ANILINO-4-(HETEROCYCLIC)AMINO-PYRIMIDINES PRKCA, PRKCG, PRKCH TDO2 2576/4885CDK5 69/4885CDK5R1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.